This year’s European Haemophilia Consortium (EHC) Conference 2024 starts today! At Sobi, we’re committed to transforming the lives of people with rare and debilitating diseases and we are excited to participate once again at the EHC Conference 2024 in Sofia, Bulgaria. We look forward to participating in discussions on improving care for people living with haemophilia. You are invited to visit us at our booth! #Sobi #RareDiseases #EHC2024 #BleedingDisorders
Sobi - Swedish Orphan Biovitrum AB (publ)
Tillverkning av läkemedel
Stockholm, Stockholm County 67 942 följare
rare strength
Om oss
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We provide sustainable access to innovative therapies in the areas of haematology, immunology, and specialty indications. Today, we employ approximately 1,800 people across Europe, North America, the Middle East and Asia. In 2023, our revenue amounted to SEK 22.1 billion. The Sobi share (STO:SOBI) is listed on Nasdaq Stockholm. You can find more information about Sobi at sobi.com.
- Webbplats
-
http://www.sobi.com
Extern länk för Sobi - Swedish Orphan Biovitrum AB (publ)
- Bransch
- Tillverkning av läkemedel
- Företagsstorlek
- 1 001–5 000 anställda
- Huvudkontor
- Stockholm, Stockholm County
- Typ
- Publikt aktiebolag
- Specialistområden
- orphan drugs, hereditary metabolic disorders, haemophilia, biopharmaceuticals, patient access, rare diseases, haematology, hematology, immunology och autoimmune
Adresser
-
Primär
Norra Stationsgatan 93A
Stockholm, Stockholm County 11364, SE
Anställda på Sobi - Swedish Orphan Biovitrum AB (publ)
Uppdateringar
-
We’re proud to celebrate 10 years of collaboration with Sanofi and the World Federation of Hemophilia Humanitarian Aid Program. Together, we’re working to bridge the gap in care in under-resourced regions and over the past decade we’ve had the privilege of touching countless lives around the globe. This year our team witnessed the impact of this initiative firsthand on a trip to India, where comprehensive haemophilia care has transformed the lives of many. Learn more about the journey and the inspiring stories of resilience from patients and caregivers: https://lnkd.in/dBTWgSx9 #Sobi #RareDiseases #TreatmentForAll #haemophilia
-
We have moved! Yesterday, Sobi officially opened the doors to our new global headquarters in the Fenix Sthlm building in Hagastaden, Stockholm, Sweden. Our new office places us in a thriving healthcare and life sciences environment, close to Sweden’s largest hospital and key research institutions. This move marks an important milestone for us, providing a modern, open workspace designed to foster collaboration and innovation as we continue our mission of transforming the lives of people with rare diseases. We are excited for the future and all that we will accomplish from our new headquarters! #Sobi #RareDiseases #Innovation
-
We are proud to have signed EUCOPE’s open letter, "Building A Competitive Pharmaceutical Ecosystem For Small And Mid-Sized Innovative Companies." Together, we call on the leaders of the EU Institutions to create a supportive environment for innovative pharmaceutical companies. This will help the EU remain globally competitive, foster the development of novel therapies, and improve the lives of people living with rare diseases. Read the open letter: https://lnkd.in/eCeJk8U5 #Sobi #RareDiseases #InnovationEcosystem
-
We are proud to support Familial Mediterranean Fever (FMF) Day on 17 September. FMF is a rare autoinflammatory genetic disease that causes recurrent, painful episodes of fever, often accompanied by abdominal, chest, or joint pain. Though it is a lifelong condition that can affect individuals of any ethnic background, FMF is more common in those with Mediterranean ancestry. Autoinflammatory diseases, like FMF, remain under-recognised and are often difficult to diagnose due to their complexity and rarity. At Sobi, we stand with the FMF community and are committed to raising awareness about this challenging condition. Learn more about FMF and other autoinflammatory diseases. https://lnkd.in/dq-KyauF #Sobi #RareDiseases #FMF
-
Today, on World Lymphoma Awareness Day, we mark the 20th anniversary of this important day dedicated to raising awareness and supporting those affected by lymphoma. At Sobi, we believe in the power of honest conversations. This year’s theme, “Time for Some Honest Talk,” resonates deeply with us, emphasising the importance of open communication in navigating the emotional challenges of a lymphoma diagnosis. “The Right Words” Discussion Guide provides tools to help with difficult conversations, treatment decisions, and addressing fears and uncertainties. Access the guide https://lnkd.in/dMTyXPET Lymphoma includes over 80 subtypes, such as Diffuse Large B-cell Lymphoma (DLBCL), a type of cancer that affects white blood cells (B-cells), causing them to grow and multiply uncontrollably. Learn more from the Lymphoma Coalition https://lnkd.in/eRhusDr Let’s continue to raise awareness and show support for the lymphoma community. Together, we can make a difference. # Sobi #RareDiseases #WLAD2024 #LymphomaAwareness #TheRightWords #TalkingDLBCL
-
September is ITP Awareness Month! Immune Thrombocytopenia (ITP) is a rare autoimmune disease where the immune system attacks platelets in the blood, leading to low platelet counts and an increased risk of bleeding. This condition can be challenging for patients and their caregivers, making effective communication with healthcare providers essential. To support caregivers and patients, we’re highlighting the ITP Discussion Guide - a resource designed to facilitate conversations with healthcare providers. This guide helps ensure that specific care goals, needs, and preferences are effectively communicated, providing confidence that every important topic is addressed. Learn more and download the ITP Discussion Guide: https://lnkd.in/dQsG-5YT #Sobi #RareDiseases #breakingdownbarriersinITP #ITPawarenessmonth2024
-
Tomorrow, 7 September, is Still’s Disease Awareness Day. This is a perfect opportunity to learn more about this rare, systemic, autoinflammatory condition, which is often difficult to diagnose because of the variability in signs and symptoms. Low awareness may lead to diagnosis of other conditions first, resulting in treatments that do not target the actual disease. Delayed diagnosis is common, as Still’s disease is often confused with infection. Early detection and access to treatments are vital to the best outcomes. Learn all you need to know about Still’s Disease https://lnkd.in/dGP_NJbq #Sobi #RareDiseases #AiArthritis #StillsDay
-
We are delighted to announce that Guido Oelkers, CEO of Sobi, will speak at the Morgan Stanley 22nd Annual Global Healthcare Conference on 6 September in New York, USA. This event offers Sobi an excellent platform to engage with shareholders and leading institutional investors. We look forward to highlighting our commitment to patients and dedication to delivering value to our shareholders. #Sobi #RareDiseases #InvestorRelations
-
Join us to make a meaningful impact on patients' lives. Our global footprint is expanding, and so is the opportunity to make a difference for people with rare and debilitating diseases. If you're passionate about making a difference and want to be part of a growing team, see our open positions on LinkedIn or sobi.com. Your next career move is just a click away. https://lnkd.in/d2qJ2hH #Sobi #RareDiseases #RareStrength #CareerOpportunities
Anslutna sidor
Liknande sidor
Finansiering
Senaste finansieringsrunda
Lån efter börsintroduktion274 917 390,00 US$